Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...

BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

Robot-assisted neobladder yields better perioperative and functional outcomes with similar long-term survival to open surgery ...

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

Around one in 10 women will develop ovarian cysts at some point during their lives, and while the prospect of a cyst growing ...

a No deaths were reported. b Three patients underwent cystectomy for atrophic bladder and four female patients for cervical cancer. c Percentage calculated on a total of 27 patients. d Forty male ...

When it comes to cancer care, precision isn rsquo;t a luxury mdash;it rsquo;s an essential aspect of the treatment .

The SunRISe-2 study, in people with muscle-invasive bladder cancer (MIBC) who were not receiving surgery to remove the bladder (cystectomy) and nearby lymph nodes, has been discontinued after it ...